Bloomage Biotechnology Corporation Limited(688363)
2021 performance report of the audit committee of the board of directors
In accordance with the standards for the governance of listed companies, the guidelines for the operation of the audit committee of the board of directors of listed companies on Shanghai Stock Exchange, the Bloomage Biotechnology Corporation Limited(688363) articles of association, the working rules of the Bloomage Biotechnology Corporation Limited(688363) audit committee and other relevant provisions, the audit committee of the board of directors of Bloomage Biotechnology Corporation Limited(688363) (hereinafter referred to as the “company”) was diligent and responsible in 2021 (hereinafter referred to as the “reporting period”), Actively perform the duties of the audit committee, and now report the performance of the audit committee in 2021 as follows:
1、 Basic information of the audit committee
The audit committee of the first board of directors of the company is composed of independent directors Ms. Xiao Xing, Mr. Li Junqing and director Ms. Liu Aihua. Among them, Ms. Xiao Xing, doctoral supervisor, director and professor of accounting department of Tsinghua University, serves as the chairman of the audit committee as an accounting professional.
2、 Annual meeting of the audit committee
The meeting of the company’s audit committee in 2021 and the deliberation of the proposal are as follows:
Date of convening meeting content important opinions and suggestions other performance of duties
In March 2021, the Committee reviewed the proposal for 2020. In 2021, the committee members paid attention to the audit work focusing on the marketing expenses and the investment effectiveness of the raised investment projects in the monthly report on the 29th of the raised funds and other audit plans, so as to enhance the benefits and increase the marketing expenses significantly The daily audit department reports the audit of operating benefits and the related party transactions
In April 2021, it was suggested that the company should pay attention to the increase of profits
On June 28, the report length of the first quarter of 2014 lagged behind the growth of revenue
Report the situation, pay attention to the attribute of science and innovation,
Strengthen R & D
In August 2021, the Committee reviewed the company’s proposal. Before growth, the committee members paid attention to the company’s internal audit findings, the semi annual report on June 29, revenue contribution and other aspects, and suggested to pay attention to operation and management, and listen to the audit work of the audit department on the consumer market and raw material market
Comparative analysis of the reporting field to
Decide how much the company will take in the future
Diversified strategy or focused war
slightly
Company reviewed in October 2021 none
March 25 third quarter report
Sue
3、 Performance of the Audit Committee during the reporting period
1. Supervise and evaluate external audit
During the reporting period, the members of the audit committee and the external auditor Zhitong Certified Public Accountants (special general partnership) communicated in an appropriate way on the audit of the 2020 annual financial statements, such as the audit schedule, the members of the audit project team, the important areas concerned by the auditors, the matters recommended by the auditors and the concerns of the management, and reviewed the 2020 annual report of the company, Members of the audit committee believe that Zhitong Certified Public Accountants (special general partnership) can perform audit duties independently and diligently in strict accordance with the practice standards of Chinese certified public accountants, and better complete various audit tasks.
2. Supervise and evaluate internal audit
During the reporting period, we listened to the reports on the work of the Audit Department of the company, including the annual work plan of 2021 and the audit findings of the audit department’s special audit on key processes such as sales business, cost control, procurement business process and outsourcing processing business in the first half of 2021. We found no major problems in the internal audit of the company.
3. Review the company’s financial information and its disclosure
During the reporting period, the audit committee reviewed the audited financial report of the company in 2020 and the unaudited financial reports such as the first quarter report, semi annual report and third quarter report of 2021. We believe that the financial report of the company is true, accurate and complete, and objectively reflects the company’s operating conditions, operating results and cash flow.
4. Supervise and evaluate the company’s internal control
During the reporting period, we reviewed and approved the Bloomage Biotechnology Corporation Limited(688363) 2020 annual internal control evaluation report and listened to the report on internal control by the head of the Audit Department of the company. We found no major defects related to the internal control of the company’s financial reports and non-financial reports. We believe that the company has established a relatively perfect internal control system.
4、 Overall evaluation
During the reporting period, in accordance with the standards for the governance of listed companies, the guidelines for the operation of the audit committee of the board of directors of listed companies of Shanghai Stock Exchange, the Bloomage Biotechnology Corporation Limited(688363) articles of association, the rules for the work of Bloomage Biotechnology Corporation Limited(688363) audit committee and other relevant provisions, we were diligent and conscientious, and effectively played the role of review, supervision and guidance. In 2022, We will further strengthen communication with the company’s audit department, external auditors and management, fulfill our duties, give full play to the supervision function of the audit committee, and safeguard the common interests of the company and all shareholders.
(no text below)
